- Home
- TBLA vs OCS Comparison
TBLA vs OCS Comparison
Compare TBLA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBLA | OCS |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TBLA | OCS |
|---|---|---|
| Price | $3.09 | $26.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.00 | ★ $41.86 |
| AVG Volume (30 Days) | ★ 2.1M | 399.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.95 | $418.43 |
| Revenue Next Year | $5.62 | $892.34 |
| P/E Ratio | $42.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.63 | $14.00 |
| 52 Week High | $4.65 | $30.68 |
Technical Indicators
Market Signals| Indicator | TBLA | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 40.78 |
| Support Level | $3.03 | $19.00 |
| Resistance Level | $3.56 | $29.23 |
| Average True Range (ATR) | 0.17 | 1.30 |
| MACD | 0.02 | -0.45 |
| Stochastic Oscillator | 41.73 | 15.04 |
Price Performance
Historical ComparisonAbout TBLA Taboola.com Ltd.
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.